Filing Flows › Crispr Therapeutics AG (CRSP) › Q3 2026 › vs Q2 2026
Crispr Therapeutics AG (CRSP) Q3 2026 vs Q2 2026 (quarter over quarter)
Crispr Therapeutics AG's revenue rose $2.5M (+24%) from $10.2M in Q2 2026 to $12.7M in Q3 2026. The biggest changes: Collaboration Revenue +$2.3M (+23%); Grant +$165K (+91%).
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Collaboration Revenue | $12.3M | $10.0M | $2.3M | +23% |
| Grant | $346K | $181K | $165K | +91% |
| Revenue | $12.7M | $10.2M | $2.5M | +24% |
| Other income, net | $18.7M | $27.1M | −$8.4M | -31% |
| Net loss | $111M | $91.2M | $20.3M | +22% |
| Costs & expenses | $143M | $128M | $14.4M | +11% |
| Operating costs | $143M | $127M | $15.3M | +12% |
| Income tax | $74K | $960K | −$886K | -92% |
| Research & development | $71.9M | $67.2M | $4.7M | +7% |
| General & admin | $17.9M | $17.6M | $314K | +2% |
| Other operating costs | $53.0M | $42.7M | $10.2M | +24% |
| Operating cash sources | $112M | $105M | $6.8M | +6% |
| Depreciation & amortization | $4.2M | $4.3M | −$42K | -1% |
| Share-based compensation | $18.0M | $17.3M | $645K | +4% |
| Cash used in operations | $89.7M | $83.5M | $6.2M | +7% |
| Net loss absorbed | $111M | $91.2M | $20.3M | +22% |
| Working capital & other | $446K | $13.9M | −$13.5M | -97% |
Questions
How much did Crispr Therapeutics AG's revenue grow quarter over quarter in Q3 2026?
Crispr Therapeutics AG's revenue rose $2.5M (+24%) from $10.2M in Q2 2026 to $12.7M in Q3 2026.
What drove Crispr Therapeutics AG's revenue change in Q3 2026?
Collaboration Revenue +$2.3M (+23%); Grant +$165K (+91%).